Know what’s inside:
In-Vitro ADME
Professionalism and Flexibility
The In-Vitro ADME team of the GBA Group combines professionalism of the pharmaceutical industry with the flexibility to adapt standard assays for your specific challenges. We use a consultative approach to set-up tailor-made assays together with you. Studies are conducted to meet regulatory requirements.
Evaluate the “druggability” of your compounds by the following set of in vitro ADME assays.
Your direct contact
MUDr. Maria Li
Director Business Development
Mobile: +49 173 889 4288
Mail: m.li@gba-pharma.com
Physico-Chemical Parameters
- Chemical stability
- Aqueous solubility
Stability in Biological Matrices
- Blood
- Plasma
- Intestinal fluids
- Further matrices on request
- All preclinical species available
Membrane Permeability
- PAMPA
- Artificial BBB
- Bidirectional Caco2
- PgP interaction
- Nuclear uptake
Interaction with Drug Transporters*
- ABC-ATP binding
- SLC transporters:
inhibition/uptake - PgP interaction
*in cooperation
Protein Binding Mechanism
- PPB (crossfiltration or Rapid Equilibrium Dialysis)
- SPB (crossfiltration or Rapid Equilibrium Dialysis)
- Blood partitioning
- Microsomal binding
Brain Tissue Binding
- Rat, mice tissue
- Ultrafiltration
- Rapid Equilibrium Dialysis
Metabolic Stability
- Liver or intestinal microsomes
- Liver or intestinal S9 fraction
- Hepatocytes
- All preclinical species available
Reactive Metabolite Trapping
- Liver microsomes
- GSH
Metabolite Identification
- Liver or intestinal microsomes
- Liver or intestinal S9 fraction
- Hepatocytes
- Metabolic pathway
CYP Inhibition
- Recombinant human CYPs
- IC₅₀ determination
- Human liver microsomes*
- Mode of inhibition, inhibition kinetics
*according to EMA/FDA Guidelines
CYP Induction
- Hepa RG®
- Human hepatocytes
- Functional activity
- mRNA
CYP Phenotyping
- Recombinant human CYPs
- Loss of parent compound
- Clint
- Half-Life
- Formation of major Phase 1 metabolites and metabolic Pathway Elucidation
